Ando Y - Search Results

1

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.

Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, Tabatabai G. Wick A, et al. Among authors: ando y. Clin Cancer Res. 2021 May 15;27(10):2723-2733. doi: 10.1158/1078-0432.CCR-20-4256. Epub 2021 Feb 23. Clin Cancer Res. 2021. PMID: 33622704 Clinical Trial.

2

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.

Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T. Ando Y, et al. Cancer Sci. 2014 Mar;105(3):347-53. doi: 10.1111/cas.12350. Epub 2014 Feb 13. Cancer Sci. 2014. PMID: 24405565 Free PMC article. Clinical Trial.

3

Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.

Inada-Inoue M, Ando Y, Kawada K, Mitsuma A, Sawaki M, Yokoyama T, Sunakawa Y, Ishida H, Araki K, Yamashita K, Mizuno K, Nagashima F, Takekura A, Nagamatsu K, Sasaki Y. Inada-Inoue M, et al. Among authors: ando y. Cancer Chemother Pharmacol. 2014 Apr;73(4):673-83. doi: 10.1007/s00280-014-2374-3. Epub 2014 Jan 24. Cancer Chemother Pharmacol. 2014. PMID: 24464355 Clinical Trial.

4

A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.

Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW. Shou Y, et al. Among authors: ando y. Clin Cancer Res. 2015 Feb 1;21(3):585-93. doi: 10.1158/1078-0432.CCR-13-1711. Epub 2014 Dec 3. Clin Cancer Res. 2015. PMID: 25473003

5

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.

Shibata T, Ebata T, Fujita K, Shimokata T, Maeda O, Mitsuma A, Sasaki Y, Nagino M, Ando Y. Shibata T, et al. Among authors: ando y. Cancer Sci. 2016 Feb;107(2):168-72. doi: 10.1111/cas.12851. Epub 2016 Feb 2. Cancer Sci. 2016. PMID: 26595259 Free PMC article. Clinical Trial.

6

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors.

Minami H, Ando Y, Ma BB, Hsiang Lee J, Momota H, Fujiwara Y, Li L, Fukino K, Ito K, Tajima T, Mori A, Lin CC. Minami H, et al. Among authors: ando y. Cancer Sci. 2016 Oct;107(10):1477-1483. doi: 10.1111/cas.13022. Epub 2016 Sep 24. Cancer Sci. 2016. PMID: 27467121 Free PMC article. Clinical Trial.

7

Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.

Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y. Ando Y, et al. Cancer Sci. 2019 Mar;110(3):1021-1031. doi: 10.1111/cas.13923. Epub 2019 Jan 30. Cancer Sci. 2019. PMID: 30588709 Free PMC article. Clinical Trial.

8

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter.

Maeda O, Shimokata T, Ando Y. Maeda O, et al. Among authors: ando y. Clin Cancer Res. 2020 Jul 15;26(14):3889. doi: 10.1158/1078-0432.CCR-20-0156. Clin Cancer Res. 2020. PMID: 32669271 No abstract available.

9

Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.

Nishida Y, Hamada S, Urakawa H, Ikuta K, Sakai T, Koike H, Ito K, Emoto R, Ando Y, Matsui S. Nishida Y, et al. Among authors: ando y. Cancer Sci. 2020 Nov;111(11):4187-4194. doi: 10.1111/cas.14626. Epub 2020 Sep 5. Cancer Sci. 2020. PMID: 32816351 Free PMC article. Clinical Trial.

10

Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.

Minami H, Ando Y, Tamura K, Tajima T, Isaacs R. Minami H, et al. Among authors: ando y. Anticancer Res. 2020 Sep;40(9):5229-5235. doi: 10.21873/anticanres.14526. Anticancer Res. 2020. PMID: 32878811 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,771 results

Search Page